NasdaqGS - Delayed Quote • USD
scPharmaceuticals Inc. (SCPH)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 6 |
Avg. Estimate | -0.44 | -0.39 | -1.48 | -0.62 |
Low Estimate | -0.51 | -0.49 | -1.75 | -1.15 |
High Estimate | -0.39 | -0.35 | -1.3 | -0.26 |
Year Ago EPS | -0.3 | -0.36 | -1.42 | -1.48 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 6 |
Avg. Estimate | 5.98M | 8.25M | 40.01M | 97.75M |
Low Estimate | 3.95M | 6.91M | 36.54M | 81.91M |
High Estimate | 7.5M | 9.4M | 45.6M | 134.7M |
Year Ago Sales | 2.06M | -- | 13.59M | 40.01M |
Sales Growth (year/est) | 189.90% | -- | 194.30% | 144.30% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.36 | -0.37 | -0.36 | -0.42 |
EPS Actual | -0.3 | -0.36 | -0.41 | -0.35 |
Difference | 0.06 | 0.01 | -0.05 | 0.07 |
Surprise % | 16.70% | 2.70% | -13.90% | 16.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.44 | -0.39 | -1.48 | -0.62 |
7 Days Ago | -0.44 | -0.39 | -1.48 | -0.62 |
30 Days Ago | -0.44 | -0.39 | -1.48 | -0.62 |
60 Days Ago | -0.37 | -0.34 | -1.22 | -0.48 |
90 Days Ago | -0.36 | -0.32 | -1.19 | -0.45 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | SCPH | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -46.70% | -- | -- | 6.50% |
Next Qtr. | -8.30% | -- | -- | 12.00% |
Current Year | -4.20% | -- | -- | 5.30% |
Next Year | 58.10% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
Initiated | Craig-Hallum: Buy | 9/7/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/2/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 7/19/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 6/8/2023 |
Related Tickers
MIST Milestone Pharmaceuticals Inc.
1.5400
-3.14%
LIFE aTyr Pharma, Inc.
1.5700
-1.57%
LYRA Lyra Therapeutics, Inc.
4.7200
-8.70%
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
MGTX MeiraGTx Holdings plc
4.8000
+1.91%
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
SAVAW Cassava Sciences, Inc.
0.4200
+35.48%
NGNE Neurogene Inc.
29.96
+0.30%
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%